Byondis Announces First Patient Dosed in Phase 1 Clinical Trial of Novel SIRPα-Directed Monoclonal Antibody BYON4228 in Patients With Advanced or Metastatic Solid Tumors

Contributed by: Business Wire

Logo

Images

Louis Denis, MD, Chief Medical Officer, Byondis

Business Wire embedded0

Tags

Science

Biotechnology

Research

Pharmaceutical

Oncology

General Health

Health

Clinical Trials

Byondis B.V.

More Like This

Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 2026

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

PR Newswire associated0

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published

Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

Louis Denis, M.D., Chief Medical Officer, Byondis (Photo: Business Wire)

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer